12月30日，金达威盘中上涨2.01%，截至11:25，报19.76元/股，成交9460.59万元，换手率0.80%，总市 值120.52亿元。 资金流向方面，主力资金净流入291.90万元，特大单买入294.64万元，占比3.11%，卖出581.83万元，占 比6.15%；大单买入1555.33万元，占比16.44%，卖出976.24万元，占比10.32%。 责任编辑：小浪快报 金达威今年以来股价涨34.42%，近5个交易日涨5.84%，近20日涨5.33%，近60日涨4.55%。 资料显示，厦门金达威集团股份有限公司位于福建省厦门市海沧新阳工业区阳光西路299号，成立日期 1997年11月24日，上市日期2011年10月28日，公司主营业务涉及保健食品制造;营养食品制造。主营业 务收入构成为：营养保健食品54.57%，辅酶Q10系列22.04%，其它11.98%，维生素A系列11.41%。 金达威所属申万行业为：食品饮料-食品加工-保健品。所属概念板块包括：冰雪产业、跨境电商、多胎 概念、合成生物、中盘等。 截至9月30日，金达威股东户数3.63万，较上期减少10.95%；人均流通股16817股，较上期增 ...

12月29日，金达威跌2.42%，成交额1.42亿元。两融数据显示，当日金达威获融资买入额2620.37万元， 融资偿还2796.31万元，融资净买入-175.94万元。截至12月29日，金达威融资融券余额合计4.81亿元。 截至9月30日，金达威股东户数3.63万，较上期减少10.95%；人均流通股16817股，较上期增加12.29%。 2025年1月-9月，金达威实现营业收入26.04亿元，同比增长11.16%；归母净利润3.61亿元，同比增长 63.47%。 分红方面，金达威A股上市后累计派现27.61亿元。近三年，累计派现4.88亿元。 机构持仓方面，截止2025年9月30日，金达威十大流通股东中，香港中央结算有限公司位居第四大流通 股东，持股774.08万股，相比上期增加80.36万股。南方中证1000ETF（512100）位居第七大流通股东， 持股279.24万股，相比上期减少2.05万股。华夏中证1000ETF（159845）位居第十大流通股东，持股 165.75万股，相比上期减少4900.00股。 责任编辑：小浪快报 融资方面，金达威当日融资买入2620.37万元。当前融资余额4.79亿元，占 ...

今年以来，我国银发经济政策持续出台，旨在创新银发消费新业态新场景、优化银发经济发展环境，更 好地增进老年人福祉。 近期，陕西省民政厅、陕西省财政厅等多部门联合发布了《关于促进养老服务消费的十项措施》。此 前，吉林省、广东省、四川省、湖南省等多地均积极部署相关工作，推动银发经济发展。 中国社会科学院财经战略研究院财政研究室主任、研究员何代欣对《证券日报》记者表示，一系列政策 举措的发布，为我国银发经济的长远发展夯实了基础，也为消费提振、产业转型升级、科技成果转化创 造了更多可能性。 供给方面，养老服务不断丰富，上门照料、日间照料、短期照护、老年助餐、外出支持、针对性康复服 务、康养旅居等服务方式，为老年人提供了更多的生活与健康保障；养老产品加速迭代，适老类健身器 材、康复辅具、营养保健食品、老龄洗护化妆用品正在走进越来越多的老年人家庭。 需求方面，老年群体消费潜力巨大、喜好多样。一方面，老年人对社区养老、机构养老、居家养老的刚 性需求持续增长；另一方面，越来越多老年人愿意为"悦己"买单，带动老年旅游服务、体育健康服务、 文化娱乐活动等银发经济细分领域的销售收入显著增长。 此外，数字技术与养老产业融合加深。5G、 ...

经济水平、人口结构及健康观念迭代，全球营养保健食品市场或将长期保持5%以上的复合增速，2027 年增至2268亿美元。美国、中国及欧洲分属前三大区域市场，合计份额接近7成，欧美市场起步早，监 管体系、供应链及消费者均相对成熟，中国市场正在逐步完善中平稳增长。全球各区域市场，受消费人 群、消费需求及销售渠道等变化的影响，均在不同节奏下，迎来行业供需两端的变革，并催生了诸如 DTC品牌、电商渠道等结构性高增长机遇。 营养保健食品行业专业化分工体系成熟，各环节增长与变革同步 智通财经APP获悉，方正证券发布研报称，营养保健品市场将长期持续保持较高景气，万亿级超级市场 规模或将孕育超大市值公司;而今产业链变革正当时，结构性超高增长机会持续涌现，行业整体业绩逐 步企稳并开启向上突围，基本面改善支撑行业进入估值修复期，板块配置价值愈加显现。横向比较来 看，结合长期发展潜力，以及中短期基本面和估值水平等综合考量，推荐技源集团(603262.SH)等。 方正证券主要观点如下： 全球万亿级营养保健食品市场，供需端变革孕育高增长结构性机会 行业基本面拐头向上，板块及主流公司配置价值愈显 行业收入、利润及盈利水平和运营状况均已触底 ...

Group 1 - The core point of the article is that Baihe Co., Ltd. announced the postponement of some fundraising projects during its board meeting held on December 1, 2025 [1] - For the year 2024, Baihe Co., Ltd.'s revenue composition is primarily from nutritional health products, accounting for 99.27%, while other businesses contribute only 0.73% [1] - As of the report, Baihe Co., Ltd. has a market capitalization of 2.7 billion yuan [1]

Core Viewpoint - The stock of Kingdawei has experienced a decline recently, with a notable drop in trading volume and fluctuations in shareholder numbers, despite a year-to-date increase in stock price and significant growth in revenue and net profit [1][2]. Financial Performance - For the period from January to September 2025, Kingdawei achieved a revenue of 2.604 billion yuan, representing a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a substantial increase of 63.47% compared to the previous year [2]. Stock Market Activity - As of November 21, Kingdawei's stock price was 18.96 yuan per share, with a market capitalization of 11.564 billion yuan [1]. - The stock has increased by 28.98% year-to-date, but has seen a decline of 9.11% over the last five trading days [1]. Shareholder Information - As of September 30, the number of shareholders for Kingdawei was 36,300, a decrease of 10.95% from the previous period [2]. - The average number of circulating shares per shareholder increased by 12.29% to 16,817 shares [2]. Dividend Distribution - Kingdawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3]. - The Southern CSI 1000 ETF and Huaxia CSI 1000 ETF were among the top ten circulating shareholders, with slight changes in their holdings [3].

Core Viewpoint - The stock of Kingdawei has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 33.27%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Kingdawei reported a revenue of 2.604 billion yuan, representing a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a significant increase of 63.47% year-on-year [2]. Shareholder Information - The number of shareholders as of September 30 is 36,300, a decrease of 10.95% from the previous period [2]. - The average circulating shares per person increased by 12.29% to 16,817 shares [2]. Dividend Distribution - Kingdawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3]. - The seventh largest circulating shareholder is Southern CSI 1000 ETF, holding 2.7924 million shares, which decreased by 20,500 shares [3]. - The tenth largest circulating shareholder is Huaxia CSI 1000 ETF, holding 1.6575 million shares, with a reduction of 4,900 shares [3].

Core Viewpoint - The stock price of Kingdawei has experienced fluctuations, with a recent decline of 2.06% and a year-to-date increase of 35.78% [1] Group 1: Stock Performance - As of October 30, Kingdawei's stock price is 19.96 CNY per share, with a market capitalization of 12.174 billion CNY [1] - The stock has seen a net outflow of 694,900 CNY in principal funds, with significant buying and selling activity [1] - Over the past five trading days, the stock has decreased by 3.76%, while it has increased by 5.61% over the past 20 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kingdawei reported a revenue of 2.604 billion CNY, representing a year-on-year growth of 11.16% [2] - The net profit attributable to shareholders for the same period was 361 million CNY, showing a significant increase of 63.47% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kingdawei is 36,300, a decrease of 10.95% from the previous period [2] - The average number of circulating shares per shareholder has increased by 12.29% to 16,817 shares [2] - The company has distributed a total of 2.761 billion CNY in dividends since its A-share listing, with 488 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3] - The Southern CSI 1000 ETF and Huaxia CSI 1000 ETF are among the top ten circulating shareholders, with slight changes in their holdings [3]

Core Viewpoint - Kingdawei is a leading global enterprise in coenzyme Q10 with a full industry chain advantage, primarily engaged in the manufacturing of health food and nutritional products [1] Group 1: Business Performance - In Q3 2025, Kingdawei reported revenue of 2.604 billion yuan, ranking 4th in the industry, surpassing the industry average of 1.889 billion yuan and the median of 806 million yuan [2] - The main business segments include health food with revenue of 943 million yuan (54.57%), coenzyme Q10 series with 381 million yuan (22.04%), and vitamin A series with 197 million yuan (11.41%) [2] - The net profit for the same period was 354 million yuan, ranking 2nd in the industry, exceeding the industry average of 194 million yuan and the median of 98.96 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kingdawei's debt-to-asset ratio was 45.31%, an increase from 31.13% year-on-year, and higher than the industry average of 30.87% [3] - The gross profit margin for Q3 2025 was 40.22%, up from 38.03% year-on-year, and above the industry average of 38.90% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 10.95% to 36,300, while the average number of circulating A-shares held per shareholder increased by 12.29% to 16,800 [5] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5] Group 4: Growth Prospects - The health product market continues to expand, with Kingdawei's competitive advantages including strengthened raw material supply for health products, increased production capacity of coenzyme Q10 to 920 tons/year, and a focus on R&D with 194 valid patents [5] - Revenue for H1 2025 was 1.728 billion yuan, with a net profit of 247 million yuan, and projected net profits for 2025-2027 are 440 million, 650 million, and 790 million yuan respectively [5][6]

Core Viewpoint - Jindawei's stock price has shown significant growth this year, with a notable increase in revenue and net profit, indicating strong financial performance and investor interest [1][2]. Group 1: Stock Performance - As of October 21, Jindawei's stock price increased by 2.18% to 21.55 CNY per share, with a total market capitalization of 13.144 billion CNY [1]. - Year-to-date, Jindawei's stock price has risen by 46.60%, with a 9.39% increase over the last five trading days and a 12.01% increase over the last 20 days [1]. Group 2: Financial Performance - For the first half of 2025, Jindawei reported a revenue of 1.728 billion CNY, representing a year-on-year growth of 13.46%, and a net profit of 247 million CNY, which is a 90.12% increase compared to the previous year [2]. - Since its A-share listing, Jindawei has distributed a total of 2.761 billion CNY in dividends, with 488 million CNY distributed over the last three years [3]. Group 3: Shareholder and Institutional Holdings - As of June 30, 2025, Jindawei had 40,700 shareholders, a decrease of 4.30% from the previous period, with an average of 14,976 circulating shares per shareholder, an increase of 4.50% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.5915 million shares, and Southern CSI 1000 ETF, which increased its holdings by 521,500 shares [3].